How to Read Thymalin COA? (Batch Verification Guide)

A batch of thymalin peptide arrives with a document titled 'Certificate of Analysis'. Most researchers glance at it, confirm a purity percentage somewhere above 95%, and assume the rest is formality. That assumption costs labs months of failed experiments and thousands of dollars in wasted compound. The COA is the only verifiable proof that what you ordered matches what's in the vial. It documents HPLC purity, mass spectrometry identity confirmation, endotoxin load, and sterility verification. One misread metric means the difference between reliable data and contaminated results.

Our team has reviewed hundreds of peptide COAs across multiple suppliers. Real Peptides included. And we've found that the gap between a legitimate research-grade product and a substandard batch shows up in four specific sections of that document. Most guides tell you to 'check the purity number.' This one explains what HPLC chromatograms actually measure, why mass spectrometry matters more than purity for identity verification, and which endotoxin threshold disqualifies a peptide from in-vivo work entirely.

How do you properly read a thymalin Certificate of Analysis?

To read a thymalin COA, verify four critical sections: HPLC purity (target ≥98%), mass spectrometry confirming the expected molecular weight (±1 Da tolerance), endotoxin levels below 1.0 EU/mg for research use, and peptide content by mass (mg per vial). Each section uses a different analytical method. HPLC for purity, MS for identity, LAL assay for endotoxins. And misreading any one invalidates the batch for rigorous research protocols.

The COA isn't a product description. It's third-party laboratory verification. Every batch of peptide synthesised should generate a unique COA tied to that specific lot number. If the document you received is generic, undated, or lists no lot number, it's not a real COA. What follows covers how to decode HPLC chromatograms without a chemistry degree, how to spot red flags in mass spec data, and what endotoxin contamination means for your protocol design.

Step 1: Verify Lot Number and Peptide Identity Match Your Order

Before analysing any analytical data, confirm that the COA's lot number matches the vial label and that the peptide name listed is thymalin (or its synonyms: thymogen, thymic peptide, Tα1 analogue). A COA from a different batch. Even of the same peptide. Does not validate your current vial. Peptide synthesis is batch-specific; purity and identity can vary across production runs.

Look for a 'Product Name' or 'Peptide Sequence' field. Thymalin is typically listed as a dipeptide or tetrapeptide sequence depending on the specific analogue. If the sequence doesn't match published thymalin structures, contact the supplier before proceeding. Our experience shows that mislabeling. Rare but not impossible. Usually surfaces here first.

Check the issuance date. COAs older than 12–18 months raise questions about storage conditions between synthesis and shipment. Lyophilised peptides stored correctly (−20°C, desiccated) remain stable for years, but a COA dated three years prior with no accompanying storage documentation is a red flag. At Real Peptides, every batch ships with a COA dated within 90 days of order fulfillment to ensure traceability.

Step 2: Decode the HPLC Purity Data and Chromatogram

HPLC (high-performance liquid chromatography) measures purity by separating the target peptide from synthesis by-products, truncated sequences, and impurities. The COA will report purity as a percentage. Typically 95–99% for research-grade peptides. The number represents the area under the main peak relative to all detected peaks in the chromatogram.

The chromatogram itself looks like a graph with time (minutes) on the X-axis and absorbance (AU or mAU) on the Y-axis. The tallest, sharpest peak is your target peptide; smaller peaks are impurities. A purity of 98.2% means the main peak accounts for 98.2% of the total integrated area. What matters more than the number itself is the baseline: a noisy baseline with multiple small peaks suggests incomplete purification. A clean baseline with one dominant peak at the expected retention time is ideal.

Retention time (Rt) should fall within a defined range for thymalin. If the COA lists an Rt of 12.4 minutes but the expected range is 11.8–12.2 minutes, the peak may not be thymalin. It could be a structurally similar impurity. Cross-check retention time consistency across batches if you're ordering repeatedly. Variability beyond ±0.3 minutes is uncommon in standardised HPLC methods.

Step 3: Confirm Molecular Weight Through Mass Spectrometry

Mass spectrometry (MS) is how you confirm identity. Not purity. The COA should list an 'Observed Mass' or 'Found m/z' value and an 'Expected Mass' or 'Calculated m/z' value. For thymalin, the expected molecular weight depends on the specific sequence. Typically 800–1200 Da for shorter analogues, higher for acetylated or modified forms.

The observed mass should fall within ±1 Da of the expected mass. A match of 1047.6 Da observed vs 1048.2 Da expected is acceptable; a deviation of 1047.6 Da vs 1053.8 Da is not. That discrepancy suggests the peptide is either incorrectly synthesised, degraded, or contaminated with a structurally similar compound.

Some COAs include MS/MS (tandem mass spectrometry) data, which fragments the peptide and verifies the amino-acid sequence directly. This is the gold standard for identity confirmation. It proves not just that the mass is correct, but that the sequence is correct. If MS/MS data is absent, the COA is relying on molecular weight alone, which is less definitive but still acceptable for most research applications.

Thymalin COA: Testing Method Comparison

What If: Thymalin COA Scenarios

What If the HPLC Purity Is 94.3% Instead of 98%?

Request a replacement batch. Purity below 95% introduces measurable impurities that interfere with dose-dependent studies. A 5.7% impurity load means nearly 60 mg of unknown compounds in a 1 g batch. Those impurities can be truncated sequences, acetylated variants, or synthesis by-products with unknown bioactivity. Running experiments on 94.3% purity peptide produces data you cannot trust because the impurity contribution is statistically significant. Reputable suppliers replace out-of-spec batches at no cost.

What If the Observed Molecular Weight Is 1051.8 Da but the Expected Weight Is 1048.2 Da?

Do not use the peptide. A 3.6 Da deviation exceeds acceptable tolerance (±1 Da) and suggests the peptide is either incorrectly synthesised, contains an unexpected modification (acetylation, oxidation), or is contaminated with a different compound. Contact the supplier immediately with the COA data. Mass spectrometry errors of this magnitude are uncommon in legitimate synthesis. If the supplier cannot explain the discrepancy or provide corrected documentation, assume the batch is compromised.

What If the COA Shows Endotoxin Levels of 2.3 EU/mg?

The peptide is unsuitable for cell culture or in-vivo use. Endotoxin contamination above 1.0 EU/mg activates immune responses (cytokine release, NF-κB pathway activation) that confound experimental outcomes. Your results reflect endotoxin effects, not peptide effects. Endotoxin contamination typically originates from bacterial expression systems or inadequate purification. There is no safe way to remove endotoxins post-synthesis at the research scale. Request a replacement batch with documented endotoxin levels <0.5 EU/mg.

The Unvarnished Truth About Thymalin COA Interpretation

Here's the honest answer: most researchers treat the COA as a formality because they assume the supplier already verified everything. That assumption is what allows substandard peptides to circulate. A COA is only as reliable as the laboratory that issued it. And not all third-party labs use standardised methods or calibrated equipment. We've seen COAs report 99% purity based on UV absorbance alone (not HPLC separation), list molecular weights without showing the actual MS spectrum, and omit endotoxin testing entirely.

If the COA doesn't include chromatograms, mass spectra, or raw endotoxin assay data. Just summary numbers. Ask for the full analytical report. A legitimate supplier provides it immediately. A supplier that resists, deflects, or claims proprietary restrictions is not operating transparently. The COA exists to prove the peptide meets specification; if the data behind the summary isn't available, the summary is unverifiable.

The second uncomfortable reality: even COAs from accredited labs can be misread. A 98.5% purity sounds excellent until you notice the retention time is off by 0.8 minutes from the expected range, suggesting the main peak isn't thymalin at all. Or the molecular weight matches within tolerance, but the peptide content by mass is only 3.2 mg in a vial labeled 5 mg. Meaning 36% of the lyophilised powder is excipient, not active compound. These discrepancies are findable if you know where to look. Most researchers don't.

Recognising Red Flags in Peptide Documentation

Beyond the COA itself, several documentation patterns suggest quality-control gaps. Generic COAs. Documents that list the peptide name but no lot number, no synthesis date, and no testing date. Are not batch-specific. They're templates. A batch-specific COA must tie directly to the vial in your hand.

Missing test methods are another warning sign. The COA should state how purity was measured (HPLC method, column type, mobile phase), how molecular weight was confirmed (ESI-MS, MALDI-TOF), and how endotoxins were quantified (LAL kinetic chromogenic assay, gel-clot method). If those methods aren't listed, the results are unverifiable. You cannot replicate or challenge data with no documented methodology.

Inconsistent formatting across batches from the same supplier raises questions. Professional synthesis facilities use standardised COA templates with consistent formatting, test order, and reporting units. If one batch reports purity as '98.2%' and another as '>95%', the second batch wasn't tested. It was estimated. That estimation might be correct, but it's not verification.

At Real Peptides, every COA includes full chromatograms, mass spectra with labeled peaks, and endotoxin assay raw data. Batch-to-batch consistency in formatting and test methodology is how we ensure traceability across thousands of shipments. If you're working with a supplier whose COAs vary wildly in structure or completeness, that's a quality-control issue. Not a documentation quirk.

The most reliable way to validate a peptide isn't reading the COA alone. It's comparing COA data across multiple batches from the same supplier. Consistent retention times, molecular weights, and purity percentages across batches indicate standardised synthesis and purification. High variability suggests process inconsistency, which compounds experimental error over time. If you're designing multi-year studies, batch-to-batch reproducibility matters as much as the initial purity specification.

Reading a thymalin COA correctly is the baseline requirement for reproducible research. It's not vendor trust. It's independent verification that the compound in your protocol matches the compound in the literature. If you can't decode the chromatogram, confirm the molecular weight, or interpret the endotoxin data, you're operating on faith instead of evidence. And in biological research, faith doesn't replicate.